COMPARE · Reviewed August 4, 2026
EHC vs UHS
Verdict: Side-by-side breakdown using the Bull Rankings model. EHC scored 70.4, UHS scored 70.0 — EHC leads.
Compare another set
EHC
Encompass Health Corporation
70.4
$110.50 · $11.0B
fundamentals as of
Score gap
0.4
EHC leads
UHS
Universal Health Services, Inc.
70
$167.87 · $10.2B
fundamentals as of
The model, pillar by pillar (0–100 each)
EHC
stronger →← stronger
UHS
69
Qualityreturns · margins · balance sheet
69
76
Growthrevenue & earnings expansion
60
67
Valuevaluation vs sector peers
83
EHC and UHS split the three pillars evenly.
Fundamentals, head-to-head
EHC
UHS
$464mC
FCF
$913mC+
+10.0%B
Rev
+10.4%B
0.83C+
D/E
0.69C+
18.9xA-
P/E
6.9xA
0.41A
PEG
1.20B+
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
EHC
UHS
4% below
Price vs fair valuelower is cheaper
28% below
~5%/yr
Growth the price implies10-yr FCF · lower = less priced in
~-3%/yr
-4%
1-yr DCF upside
+31%
+4%
5-yr DCF upside
+38%
+17%
10-yr DCF upside
+49%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
EHC
Why this score
- Raising its dividend
UHS
Why this score
- Buying back stock
The companies
EHCEncompass Health Corporation
Why now
Medical Care Facilities · market cap $11.0b. 14% off the 52-week high of $127.99. Revenue growing +10%, comfortably above the S&P median. PEG 0.41 — paying under fair value for the growth rate. 12 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $140.50 (implying +27% upside).
Moat
ROE 24% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately.
Risk
Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
UHSUniversal Health Services, Inc.
Why now
Medical Care Facilities · market cap $10.2b. Down 32% from 52-week high of $246.33 — deep drawdown territory. Revenue growing +10%, comfortably above the S&P median. 17 sell-side analysts rate this a Buy with a mean 1-yr target of $193.47 (implying +15% upside).
Moat
ROE 20% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately.
Risk
Down 32% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.